Abstract
Autoantibodies against tumor-associated antigens (TAAs) such as insulin-like growth factor II mRNA-binding proteins (IMPs), p53, c-myc, and survivin were analyzed in patients with hepatocellular carcinoma (HCC), using recombinant proteins of these antigens. Eight of 86 (9.3%) HCC patients had one or more of these autoantibodies. However, serum alpha-fetoprotein (AFP) levels ranged within normal limits in HCC patients with anti-TAAs except for one case with anti-IMP1. One of the HCC patients had autoantibodies against IMP1, IMP3 and p53 before the diagnosis of HCC. These findings may indicate that anti-TAAs seem to be supplementary serological markers for the diagnosis of HCC in AFP-negative cases and that autoantibodies against IMP1, IMP3 and p53 are candidates for predictive markers of HCC development.
MeSH terms
-
Antigens, Neoplasm / chemistry*
-
Autoantibodies / chemistry*
-
Biomarkers, Tumor / metabolism
-
Blotting, Western
-
Carcinoma, Hepatocellular / diagnosis
-
Carcinoma, Hepatocellular / metabolism*
-
DNA, Complementary / metabolism
-
Enzyme-Linked Immunosorbent Assay
-
Fibrosis
-
Humans
-
Inhibitor of Apoptosis Proteins
-
Liver / metabolism
-
Liver Neoplasms / diagnosis
-
Liver Neoplasms / metabolism*
-
Microtubule-Associated Proteins / metabolism
-
Neoplasm Proteins / metabolism
-
Proto-Oncogene Proteins c-myc / metabolism
-
RNA, Messenger / metabolism
-
Recombinant Proteins / chemistry
-
Survivin
-
Tumor Suppressor Protein p53 / metabolism
-
alpha-Fetoproteins / biosynthesis
Substances
-
Antigens, Neoplasm
-
Autoantibodies
-
BIRC5 protein, human
-
Biomarkers, Tumor
-
DNA, Complementary
-
Inhibitor of Apoptosis Proteins
-
Microtubule-Associated Proteins
-
Neoplasm Proteins
-
Proto-Oncogene Proteins c-myc
-
RNA, Messenger
-
Recombinant Proteins
-
Survivin
-
Tumor Suppressor Protein p53
-
alpha-Fetoproteins